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Summary
Background Praziquantel has been the drug of choice for schistosomiasis control for more than 40 years, yet 
surprisingly, the optimal dose for children younger than 4 years is not known. We aimed to assess the efficacy and 
safety of escalating praziquantel dosages in preschool-aged children (PSAC).
Methods We did a randomised controlled, parallel-group, single-blind, dose-ranging, phase 2 trial in PSAC (2–5 years) 
and school-aged children (SAC; aged 6–15 years) as a comparator group in southern Côte d’Ivoire. Children were 
randomly assigned (1:1:1:1) to 20 mg/kg, 40 mg/kg, or 60 mg/kg praziquantel or placebo. Participants, investigators, 
and laboratory technicians were masked to group assignment, while the investigator providing treatment was aware 
of the treatment group. The primary objective was to estimate the nature of the dose–response relation in terms of 
cure rate using the Kato Katz technique. Dose–response curves were estimated using Emax models. Available case 
analysis was done including all participants with primary endpoint data. This trial is registered with International 
Standard Randomised Controlled Trial, number ISRCTN15280205.
Findings Between Nov 11, 2014, and Feb 18, 2015, 660 PSAC and 225 SAC were assessed for eligibility; of whom 
161 (24%) PSAC and 180 (80%) SAC had a detectable Schistosoma mansoni infection. 161 PSAC were randomly allocated 
of whom 154 received treatment: 42 were assigned to 20 mg/kg praziquantel, of whom 40 received treatment; 38 were 
assigned to 40 mg/kg praziquantel, of whom 38 received treatment; 41 were assigned to 60 mg/kg praziquantel, of 
whom 39 received treatment; and 40 were assigned to placebo, of whom 37 received placebo. 180 SAC were randomly 
allocated of whom 177 received treatment: 49 were assigned to 20 mg/kg praziquantel, of whom 47 received treatment; 
46 were assigned to 40 mg/kg praziquantel, of whom 46 received treatment; 42 were assigned to 60 mg/kg praziquantel, 
of whom 42 received treatment; and 43 were assigned to placebo, of whom 43 received treatment. Follow-up (available-
case) data were available for 143 PSAC and 174 SAC. In PSAC, the 20 mg/kg dose resulted in cure in 23 children (62%; 
95% CI 44·8–77·5), 40 mg/kg in 26 children (72%; 54·8–85·8), 60 mg/kg in 25 children (71%; 53·7–85·4), and 
placebo in 13 children (37%; 21·5–55·1). In SAC, the 20 mg/kg dose resulted in cure in 14 children (30%; 95% CI 
17·7–45·8), 40 mg/kg in 31 children (69%; 53·4–81·8), 60 mg/kg in 34 children (83%; 67·9–92·8), and placebo in five 
children (12%; 4·0–25·6). For both age groups, the number of adverse events was similar among the three praziquantel 
treatment groups, with fewer adverse events observed in the placebo groups. The most common adverse events in 
PSAC were diarrhoea (11 [9%] of 124) and stomach ache (ten [8%]) and in SAC were diarrhoea (50 [28%] of 177), 
stomach ache (66 [37%]), and vomiting (26 [15%]) 3 h post treatment. No serious adverse events were reported.
Interpretation Praziquantel shows a flat dose-response and overall lower efficacy in PSAC compared with in SAC. 
In the absence of treatment alternatives, a single dose of praziquantel of 40 mg/kg, recommended by the WHO for 
S mansoni infections in SAC can be endorsed for PSAC in preventive chemotherapy programmes.
Funding European Research Council.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Schistosomiasis is a major public health problem in 
many parts of the developing world, especially in sub-
Saharan Africa. The disease is caused by blood flukes 
(trematode worms) of the genus Schistosoma, with 
Schistosoma haematobium, Schistosoma japonicum, and 
Schistosoma mansoni triggering most infections.1–5 Indeed, 
more than 200 million people are infected globally, with 
about half of them suffering from morbid sequelae, 
including haematuria, dysuria, nutritional deficiencies, 
anaemia, hepatic granulomas leading to (severe) peri-
portal fibrosis and consequent portal hypertension, and 
delayed physical and cognitive development.6,7 
Praziquantel is the drug of choice for treatment of 
infections with all Schistosoma species in the frame-
work of preventive chemotherapy programmes.8 While 
Lancet Glob Health 2017; 
5: e688–98
See Comment page e640
Department of Medical 
Parasitology and Infection 
Biology, Swiss Tropical and 
Public Health Institute, 
University of Basel, Basel, 
Switzerland (J T Coulibaly PhD, 
G Panic PhD, J Kovac MSc, 
Prof J Keiser PhD); Unité de 
Formation et de Recherche 
Biosciences, Université Félix 
Houphouët-Boigny, Abidjan, 
Côte d’Ivoire (K D Silué PhD, 
J T Coulibaly); and Department 
of Epidemiology and Public 
Health, Swiss Tropical and 
Public Health Institute, Basel, 
Switzerland (J Hattendorf PhD)
Correspondence to: 
Prof Jennifer Keiser, Department 
of Medical Parasitology and 
Infection Biology, Swiss Tropical 
and Public Health Institute, 
CH-4002 Basel, Switzerland 
jennifer.keiser@unibas.ch
Articles
e689 www.thelancet.com/lancetgh   Vol 5   July 2017
school-aged children (SAC) are the main target population 
for treatment, it is becoming increasingly clear that 
younger children (<6 years) are also affected by 
schistosomiasis and suffer from morbidity.9–12 Hence, 
in 2010, WHO recommended inclusion of preschool-aged 
children (PSAC) in large scale treatment programmes. In 
the absence of an appropriate paediatric formulation, 
which is currently under development, broken or crushed 
praziquantel tablets have been recommended.13 Indeed, 
the efficacy and safety of crushed praziquantel tablets in 
infants have been assessed in several endemic settings 
mainly throughout Africa.11,14–17
Despite the above-mentioned studies, surprisingly, the 
effective dose for children younger than 4 years is not 
known. At the moment, praziquantel is widely used off-
label at a standard dose of 40 mg/kg to treat PSAC,18,19 
because this is the recommended dose used for SAC and 
adults. However, a simple extrapolation of adult 
praziquantel dosages to children is very uncertain in 
view of the maturational differences in absorption, 
metabolism, and elimination.
In more detail, the oral bioavailability of drugs might 
vary in paediatric and adult populations due to differences 
in gastric pH and emptying time, intestinal transit time, 
immaturity of secretion, and the activity of bile and 
pancreatic fluid. Drug distribution in children and adults 
differs due to changes in membrane permeability, 
plasma protein binding, and total body water. Finally, the 
immaturity of enzyme systems (cytochrome P450), 
glomerular filtration, renal tubular secretion, and tubular 
reabsorption in children account for a different excretion 
of drugs in the paediatric population compared with in 
adults.20,21 Despite this, thorough, quality, dose-finding 
clinical studies using praziquantel have not been done in 
PSAC to date.
We aimed to determine the nature of the dose–response 
of praziquantel in PSAC infected with S mansoni to 
determine the dose of praziquantel that shows an efficacy 
comparable to the standard dose of 40 mg/kg in SAC in 
an area where S mansoni is endemic.22 Our findings, 
along with concurrent investigations pertaining to the 
pharmacokinetics of praziquantel in SAC and PSAC 
(Kovač and colleagues, under preparation) might be 
pivotal to further optimise the control of schistosomiasis.
Methods
Study design and participants
We did a randomised controlled, parallel-group, single-
blind, dose-ranging, phase 2 trial was done in five villages 
located in the health district of Azaguié, southern 
Côte d’Ivoire. A detailed census was done in 
November, 2014, which generated lists of PSAC and SAC, 
including their name, age, and sex. PSAC (aged 
2–5 years) and SAC (6-15 years) were enrolled. While the 
age of SAC was assessed based on their birth certificate 
at school level, the age of PSAC was confirmed by three 
potential sources: birth certificate, child’s health card—
where the date of birth is mentioned, and the verbal 
statement of the mother in case the two previously 
mentioned documents were unavailable. The village 
census identified 141, 167, 139, and 290 PSAC (2–5 years) 
and 231 SAC (6–15 years). All PSAC (n=737) and SAC 
registered during the census were invited to participate 
to the baseline survey.
Ethical approval for the study was obtained by the 
National Ethics Committee of the Ministry of Health in 
Côte d’Ivoire (CNER, reference number 037/MSLS/
CNER-dkn) and the Ethical Committee of Northwestern 
and Central Switzerland (EKNZ; reference numner 
162/2014).
Community meetings were held to explain the purpose, 
procedures, potential risks, and benefits of the study. 
Written informed consent was obtained from parents or 
legal guardians of participants. SAC were invited to give 
Research in context
Evidence before this study
We searched PubMed for studies published before Dec 1, 2016, 
using the search terms “praziquantel”, “schistosomiasis”, “dose 
finding”, “school-aged children”, and “preschool-aged children”. 
Our search identified numerous articles on the use of 40 mg/kg 
praziquantel in school-aged children, which concluded that this 
regimen is efficacious and safe. We noted from the year 2000 
onwards, there was an increase of studies elucidating the 
efficacy and safety of crushed praziquantel (40 mg/kg dosage) 
in preschool-aged children (PSAC). Although this treatment 
regimen was deemed efficacious and safe, the nature of the 
dose-related effect has not been studied in both age groups.
Added value of this study
The results of our randomised controlled, parallel-group, 
single-blind, dose-ranging, phase 2 trial study show increasing 
cure rates and egg reduction rates (ERRs) for school-aged 
children (SAC) with escalating dosages of praziquantel, while a 
dose–response relation could not be observed in PSAC using 
the diagnostic of choice, the Kato-Katz method. The Emax model 
predicted an ERR of 99% at 65 mg/kg in SAC and an ERR 
of 95% at 50 mg/kg in PSAC, while the ERR of 99% was out of 
the observed range. Adverse events were mild and transient 
and included stomach ache, cough, diarrhoea, and vomiting.
Implications of all the available evidence
Our dose finding study supports the widely used dose 40 mg/kg 
of praziquantel for schistosomiasis morbidity control in SAC. 
Based on our results this dose can also be recommended for 
PSAC. Drug discovery efforts should be strengthened to have 
safe and effective alternative treatment options for 
schistosomiasis available in a timely manner.
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their assent by writing their name and ticking the 
following sentence, “I agree to participate in this study” 
on the assent form. Parents or legal guardians were well 
informed on the fact that the participation was voluntary 
hence, they could withdraw their children from the study 
at any time with no further obligations.
Children were assessed for the presence of an 
S mansoni infection. S mansoni-positive children were 
eligible to participate in this trial. A clinical examination 
and an oral medical history by active questioning were 
obtained from all eligible children. Of note, mothers or 
guardians of the PSAC were asked about the medical 
history on behalf of their children. Children were 
excluded and treated with a standard dose of 40 mg/kg 
praziquantel if they had taken an antimalarial or 
anthelminthic drug in the past 4 weeks or had any 
systematic illness—namely, clinical malaria (presence of 
fever plus positive rapid malaria diagnostic test [ICT 
Malaria Plasmodium falciparum (HRPII), Cape Town, 
South Africa] according to the national guidelines) or 
hepatosplenic schistosomiasis. To determine the 
presence of hepatosplenic schistosomiasis, the extension 
of the left liver lobe beneath the sternum was measured 
in centimetres from the mid-sternal line and the 
extension of the right liver lobe beneath the rib cage was 
measured in centimetres from the right mid-clavicular 
line. At the end of the study, 3 months after the inclusion 
of the first participant, all children enrolled in the study 
were offered albendazole (400 mg) and praziquantel 
(40 mg/kg) for the treatment of helminth infections.
Randomisation and masking
PSAC and SAC with a parasitologically confirmed 
S mansoni infection were stratified by light, moderate, or 
heavy baseline infection intensities and randomly 
assigned (1:1:1:1) to placebo or 20 mg/kg, 40 mg/kg, or 
60 mg/kg praziquantel using computer-generated 
stratified block randomisation codes provided by an 
independent statistician (stratified by two infection 
intensity strata; block size of eight). Children and 
laboratory technicians undertaking the diagnostics were 
masked, while the investigator delivering the treatment 
was aware of the treatment assignments. Masking was 
maintained throughout the trial until data cut off. 
Randomisation codes were released after the database 
was unlocked.
Procedures
During the baseline survey, at school level, children were 
provided with plastic containers labelled with unique 
identification numbers (IDs) and asked to deliver a fresh 
stool and urine sample. For the PSAC, mothers or 
guardians were given the plastic containers labelled with 
a unique ID and they were asked to obtain a fresh stool 
and urine sample of their child. From each participating 
child, two stool samples over two consecutive days and a 
single urine sample were collected. Stool and urine 
samples were transferred to a nearby laboratory in 
Azaguié town and examined on the day of collection. For 
the diagnosis of S mansoni, stool samples were each 
subjected to duplicate Kato-Katz thick smears (standard 
template of 41·7 mg).23 Eggs of soil-transmitted 
helminths—ie, Ascaris lumbricoides, hookworm, and 
Trichuris trichiura—were also assessed and recorded for 
each parasite species separately. A subsequent 
independent quality control of sample results (about 10%) 
was done. In brief, the result from each slide among the 
10% slides is considered correct if the following tolerance 
margin is not exceeded between the reading of 
two laboratory technicians: (1) for counts of 100 eggs or 
less, the difference between technicians’ egg counts must 
not be greater than 10 eggs; and (2) for counts of 100 eggs 
or more the difference between technicians’ egg counts 
must not be greater than 20 eggs. In case of discrepancy 
between the results of quality control and the initial 
reading, all the slides were read once again by the senior 
technician. Urine samples were subjected to the urine 
filtration technique for the diagnosis of S haematobium 
using the same quality control process. A commercially 
available Point-of-Care Circulating Cathodic Antigen 
(POC-CCA) cassette test (batch number: 34066; Rapid 
Medical Diagnostics, Pretoria, South Africa) for the 
diagnosis of S mansoni was applied on urine samples 
from the first day of samples collection. The POC-CCA 
tests were done and read as described elsewhere.24 In 
addition, a finger prick blood sample was taken, and 
thick and thin blood smears were prepared for the 
diagnosis of Plasmodium species. Blood smears were 
stained with Giemsa and examined under a microscope 
using 100 x oil immersion. The Plasmodium density was 
counted against 200 leucocytes, assuming 8000 leucocytes 
per µL of blood. If less than 10 Plasmodium were found, 
the reading was continued up to 500 leucocytes. All slides 
were double-checked by a second laboratory technician 
and only considered negative if no Plasmodium were 
detected in 100 x oil immersion field by the two 
independent microscopists. In addition, a rapid malaria 
diagnostic test was used and the haemoglobin value 
measured using a calibrated HaemoCue device 
(HaemoCue 301 system, Ängelholm, Sweden) according 
to the manufacturer’s instructions. Weight was measured 
in kg using the domestic HAMSON bathroom weighing 
scale (Graduation increments of 0·1 kg) and height was 
measured using a common builder’s measuring tape.
To assess treatment efficacy, another two stool samples 
and one urine sample were collected between 21 days 
and 25 days post-treatment for the follow-up and 
subjected to the same diagnostic approaches applied at 
the baseline survey.
Procedures
After the baseline screening and clinical examination, 
eligible participants were treated. Before treatment, each 
participant received breakfast. The breakfast comprised 
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of an equally sized piece of buttered baguette for each 
child. Praziquantel tablets (600 mg Cesol, kindly provided 
by Merck (Darmstadt, Germany) or placebo tablets 
(Fagron, Germany) were given according to the calculated 
dose per kg of bodyweight in half tablet increments 
(eg, 1·3 tablets calculated = 1·5 tablets given or 1·2 tablets 
calculated = 1 tablet given). For PSAC, tablets were 
crushed using a mortar and pestle and dissolved in a 
small volume of syrup-flavoured water. SAC and the 
mothers or guardians of PSAC were interviewed 3 h, 
24 h, 48 h, and 72 h after treatment about the occurrence 
of adverse events and mitigating drugs were provided if 
necessary. An adverse event was defined as any 
unfavourable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal or 
investigational product, whether or not related to the 
treatment. All adverse event intensities were judged by 
the study physician, following guidelines by the European 
Medicine Agency and were graded as mild, moderate, 
severe, or intolerable.
Outcomes
Our primary outcome was the cure rate (the percentage 
of egg-positive children at baseline who became egg-
negative after treatment) resulting from different doses 
of praziquantel based on the Kato-Katz method. The 
secondary outcomes were egg reduction rate (ERR) and 
the safety of different doses of praziquantel.
Statistical analysis
Simulations showed that with 36 children enrolled in 
each of the four treatment study groups (0 mg/kg, 
20 mg/kg, 40 mg/kg, and 60 mg/kg), the dose response 
prediction model should have a median precision (one 
half length of the 95% CIs) of 10% points, assuming 
associated cure rates of 2·8%, 50%, 75%,25 and 90%, 
respectively. The suggested sample size is also in line 
with the recommendations from Klingenberg in 2009.26 
To account for losses in the follow-up, the sample size 
was increased to 40 children in each study group.
Data were double entered into an Excel spreadsheet, 
transferred into EpiInfo version 3.5.2 (Centers for 
Disease Control and Prevention; Atlanta, GA, USA) and 
cross-checked.
Data were analysed with Stata version 13 (Stata Corp; 
College Station, TX, USA). Participants who had at least 
one stool sample examined each with duplicate Kato-Katz 
thick smears at follow-up, were present at treatment day, 
and not excluded due to a medical condition were 
included in the final analysis (available case analysis). 
Imputation of missing data with treatment failure or 
success was assessed in an intention-to-treat analysis.
Eggs per gram of stool (EPG) were assessed by adding 
up the egg counts from the duplicate or quadruplicate 
Kato-Katz thick smears and multiplying this number by a 
factor of 12 or six, respectively. We classified infection 
intensity as light (<100 EPG), moderate (100–399 EPG), or 
heavy (>400 EPG).27
Geometric mean egg counts were calculated as:
And the corresponding ERR 100 as:
A bootstrap resampling method with 5000 replicates 
was used to calculate 95% CIs for ERRs.
We used an Emax model as a primary model to predict the 
dose–response curves in terms of cure rates and ERRs. 
The analysis was done with the DoseFinding package 
(version 0∙9–14) of the statistical software environment R 
(version 3.3.0). Emax model was predicted in two stages. For 
binary data, first cure rates and their covariances were 
estimated on logit scale via logistic regression. In the 
second stage, doses and estimated cure rates were fitted to 
the non-linear Emax model to determine the basal effect 
(treatment effect at dose 0), the asymptotic maximum 
effect, and ED50 (the dose resulting in 0·5 * Emax). We 
converted estimates on logit scale to probabilities in the 
cure rate related dose-response figures.
 Role of funding source
The funder of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between Nov 11, 2014, and Feb 18, 2015, 968 children 
were invited to participate in the study. 660 PSAC and 
225 SAC participated in the baseline survey (figure 1). Of 
these, 161 (24%) PSAC and 180 (80%) SAC had a 
detectable S mansoni infection and were randomly 
assigned to treatment groups. In the PSAC group, 
42 were assigned to 20 mg/kg praziquantel, of whom 
40 received treatment; 38 were assigned to 40 mg/kg 
praziquantel, of whom 38 received treatment; 41 were 
assigned to 60 mg/kg praziquantel, of whom 39 received 
treatment; and 40 were assigned to placebo, of whom 
37 received placebo. In the SAC group, 49 were assigned 
to 20 mg/kg praziquantel, of whom 47 received treatment; 
46 were assigned to 40 mg/kg praziquantel, of whom 
46 received treatment; 42 were assigned to 60 mg/kg 
praziquantel, of whom 42 treatment; and 43 were 
assigned to placebo, of whom 43 received treatment.
Follow-up (available-case) data were available for 
143 PSAC and 174 SAC (figure 1). Of note, 11 PSAC and 
six SAC provided only a single stool sample at follow-up.
e1/n Σ log(EPGfollow-up + 1)   100– (  – 1)
e1/n Σ log(EPGbaseline + 1)   (  – 1) × 100
e1/n Σ log(EPG + 1)   – 1
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For all treated children, demographic and 
parasitological baseline data are shown in table 1. The 
median age, weight, height, and sex of PSAC and SAC 
were balanced among the treatment groups. At pre-
treatment, the geometric mean EPG of faeces ranged 
between 24·7 and 39·4 in the PSAC treatment groups, 
and between 71·7 and 84·1 in the SAC treatment groups 
(table 2). 129 (80%) of PSAC harboured a light S mansoni 
infection versus 93 (52%) of SAC, while about half 
(87 [49%]) of the SAC had moderate or heavy infection 
intensities versus 32 (20%) of PSAC. More than half of 
the SAC were co-infected with P falciparum (112 [62%]), 
while PSAC harboured fewer Plasmodium co-infections 
(53 [33%]). Co-infections with T trichiura were common 
in the study setting, with 56 (35%) PSAC and 97 (54%) 
SAC co-infected. By contrast, co-infections with Ascaris, 
hookworm, and S haematobium were rare, and ranged 
between 0% and 11% in the different treatment groups. 
Haemoglobin values were in the normal range with 
median values between 10·5 and 11·3 in PSAC and 
between 11·4 and 12·0 in SAC (table 1).
In PSAC, based on the Kato-Katz technique, both cure 
rates and ERRs increased only incrementally starting at 
20 mg/kg. In more detail, cure rate and ERR (geometric 
mean) for the 20 mg/kg group were 62·1% (95% CI 
44·8–77·5) and 90·7% (82·0–95·7), respectively. In the 
40 mg/kg and 60 mg/kg treatment groups, similar cure 
rates (72·2% [95% CI 54·8–85·8] and 71·4% [53·7–85·4], 
respectively) were observed (table 2; figure 2). The 
corresponding ERRs (geometric mean) were 94·8% 
(95% CI 89·1–98·0) and 95·8% (90·2–98·5), respectively. 
PSAC in the placebo group, S mansoni eggs were not 
detected in a proportion of 37·1% (95% CI 21·5–55·1) of 
children with a corresponding ERR of 80·1% (66·3–88·9). 
968 children invited to participate to the study (493 [51%] boys, 475 [49%] girls)
660 PSAC assessed for eligibility 225 SAC assessed for eligibility
161 PSAC randomly assigned to treatment groups
499 S mansoni negative 45 S mansoni negative
180 SAC randomly assigned to treatment groups
40 assigned to 
 placebo
3 absent at 
 treatment 
 day
2 absent at 
 treatment 
 day
0 absent at 
 treatment 
 day
2 absent at 
 treatment 
 day
1 excluded
 due to 
 medical 
 condition
2 absent at 
 treatment 
 day
42 assigned to 
 praziquantel 
 20 mg/kg
38 assigned to 
 praziquantel
 40 mg/kg
41 assigned to 
 praziquantel 
 60 mg/kg
43 assigned to 
 placebo
49 assigned to 
 praziquantel 
 20 mg/kg
77 PSAC absent during the survey
6 SAC absent during the survey
46 assigned to 
 praziquantel  
 40 mg/kg
42 assigned to 
 praziquantel 
 60 mg/kg
37 received 
 placebo
40 received 
 praziquantel 
 20 mg/kg
38 received 
 praziquantel
 40 mg/kg
39 received 
 praziquantel 
 60 mg/kg
42 received 
 placebo
47 received 
 praziquantel
 20 mg/kg
46 received 
 praziquantel 
 40 mg/kg
42 received 
 praziquantel
 60 mg/kg
2 absent at 
 follow-up
3 absent at 
 follow-up
2 absent at 
 follow-up 
2 received an 
 incorrect dose
4 absent at 
 follow-up
0 absent at 
 follow-up
1 absent at 
 follow-up
1 absent at 
 follow-up
1 absent at 
 follow-up 
3 received an 
 incorrect dose
35 analysed by 
 available case 
37 analysed by 
 available case 
36 analysed by 
 available case
35 analysed by 
 available case 
42 analysed by 
 available case
46 analysed by 
 available case 
45 analysed by 
 available case 
41 analysed by 
 available case
0 absent at 
 treatment 
 day
0 absent at 
 treatment 
 day
Figure 1: Trial profile
PSAC=preschool-aged children. SAC=school-aged children. S mansoni=Schistosomiasis mansoni. 
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The Emax model predicted that in PSAC, an ERR of 99% is 
out of the observed range, but an ERR of 95% is estimated 
at 50 mg/kg (figure 3). ERRs based on arithmetic means 
are shown in table 2.
The observed cure rates in SAC increased with 
escalating dosages (table 2). The 20 mg/kg dose resulted 
in cure in 14 (30·4%; 95% CI 17·7–45·8) children, the 
40 mg/kg resulted in cure of 31 (68·9%; 53·4–81·8) 
children, and the 60 mg/kg dose resulted in cure of 
34 (82·9%; 67·9–92·8) children based on the Kato-Katz 
method. Egg reduction rates (geometric mean) were 
moderate for the 20 mg/kg dose (84·2% 
[95% CI 70·9–91·5]) and high for the 40 mg/kg and 
60 mg/kg treatment groups (98·3% [96·7–99·3]) and 
99·1% [97·9–99·8], respectively. In the SAC in the 
placebo group, we observed a cure rate of 11·9% (95% CI 
4·8–25·6) and an ERR of 56·0% (36·9–69·7). ERRs based 
on arithmetic means are shown in table 2. The Emax model 
predicted an ERR of 99·0% at 65 mg/kg in SAC (figure 3).
Cure rates in PSAC were lower based on the POC-CCA 
cassette test compared with the Kato-Katz technique. 
Considering “traces” as a positive result revealed a slightly 
higher cure rate at 40 mg/kg and 60 mg/kg (32·0% 
[95% CI 14·9–53·5]) and (33·3% [15·6–55·3]) compared 
with 20 mg/kg (15·4% [4·4–34·9]) and placebo 
(21·1% [8·3–40·9]). Considering “traces” as a negative 
result yielded cure rates from 21·7% (95% CI 7·5–43·7; 
20 mg/kg) to 52·2% (30·6–73·2; 60 mg/kg). The POC-
CCA confirmed the dose–response in SAC (table 2). 
Considering “traces” as a positive result revealed cure rates 
ranging from 19·0–55·0% for 20–60 mg/kg praziquantel 
and a cure rate of 10·8 in placebo treated SAC. Considering 
“traces” as a negative result yielded cure rates from 12·1% 
(placebo) to 28·9% (20 mg/kg) to 65·7% (60 mg/kg).
Imputation of missing data with treatment failure or 
success in the intention-to-treat analysis did not change 
the observed outcomes (appendix p 3). Although our 
study was not powered to detect differences in sex, our 
study did not show an effect of sex on the efficacy of 
praziquantel (data not shown).
Three children in the 60 mg/kg treatment group were 
wrongly dosed: one received a dose of 16·8 mg/kg (PSAC), 
one a dose of 74·5 mg/kg (PSAC), and one a dose of 
36·1 mg/kg (SAC). Two PSAC in the 40 mg/kg treatment 
See Online for appendix
Preschool-aged children School-aged children
Placebo 
(n=40)
Praziquantel 
20 mg/kg 
(n=42)
Praziquantel 
40 mg/kg 
(n=38)
Praziquantel 
60 mg/kg 
(n=41)
Total 
(n=161)
Placebo 
(n=43)
Praziquantel 
20 mg/kg
(n=49)
Praziquantel 
40 mg/kg
(n=46)
Praziquantel 
60 mg/kg
(n=42)
Total
(n=180)
Age, years 4 (2–5) 4 (2–5) 4 (2–5) 4 (2–5) 4 (2–5) 8 (6–14) 9 (6–12) 9 (6–13) 9 (6–12) 9 (6–13)
Weight, kg 14 (8–18) 14 (8–18) 14 (11–18) 13 (10–18) 14 (9–18) 23 (15–46) 23 (17–40) 23 (15–41) 24 (16–40) 23 (16–43)
Height, cm 100 (83–105) 95 (77–108) 97 (84–110) 95 (81–105) 96 (80–108) 123 (108–164) 128 (106–152) 126 (106–152) 128 (107–147) 127 (106–156)
Haemoglobin (g/dL) 10·5 
(10·3–11·2)*
10·9 
(10·3–11·6)†
11·3 
(10·2–12·0)‡
10·8 
(9·9–11·8)§
10·8 
(10·1–11·6)¶
11·6 
(10·6–12·6)
11·4 
(10·8–12·4)
12·0 
(11·3–12·5)
11·6 
(10·9–12·9)
11·7 
(10·9–12·5)
Sex
Girls 17 (43%) 21 (50%) 22 (58%) 20 (49%) 80 (50%) 19 (44%) 26 (53%) 21 (46%) 25 (60%) 91 (51%)
Boys 23 (58%) 21 (50%)  16 (42%) 21 (51%) 81 (50%) 24 (56%) 23 (47%) 25 (54%) 17 (40%) 89 (49%)
Infection intensity
Light 30 (75%) 34 (81%) 32 (84%) 33 (81%) 129 (80%) 23 (54%) 26 (53%) 23 (50%) 21 (50%) 93 (52%)
Moderate 8 (20%) 6 (14%) 6 (16%) 7 (17%) 27 (17%) 15 (35%) 16 (33%) 16 (35%) 12 (29%) 59 (33%)
Heavy 2 (5%) 2 (5%) 0 1 (2%) 5 (3%) 5 (12%) 7 (14%) 7 (15%) 9 (21%) 28 (16%)
Co-infections
Schistosoma 
haematobium
1 (3%) 0 1 (3%) 3 (7%) 5 (3%) 3 (7%) 3 (6%) 3 (7%) 2 (5%) 11 (6%)
Ascaris lumbricoides 5 (13%) 1 (2%) 0 3 (7%) 9 (6%) 0 3 (6%) 5 (11%) 1 (2%) 9 (5%)
Trichuris trichiura 15 (38%) 15 (36%) 12 (32%) 14 (34%) 56 (35%) 23 (54%) 24 (49%) 27 (59%) 23 (55%) 97 (54%)
Hookworm 0 1 (2%) 1 (3%) 0 2 (1%) 4 (9%) 3 (6%) 5 (11%) 2 (5%) 14 (8%)
Plasmodium 
falciparum 
(based on thin or 
thick smear)
10 (25%) 17 (41%) 13 (34%) 13 (32%) 53 (33%) 24 (56%) 33 (67%) 28 (61%) 27 (64%) 112 (62%)
Plasmodium 
falciparum 
(based on RDT)
10 (25%) 14 (33%) 11 (26%) 13 (32%) 48 (30%) 24 (57%) 32 (67%) 27 (57%) 25 (58%) 108 (61%)
Data are median (IQR) or n (%). RDT=rapid diagnostic test. *27 participants. †34 participants. ‡30 participants. §33 participants. ¶124 participants. 
Table 1: Baseline characteristics of treatment groups
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group were treated with 60·8 mg/kg and 26·3 mg/kg, 
respectively (figure 1). Actual doses given in PSAC were 
15·2–37·5 mg/kg (20 mg/kg), 24·4–60·8 (40 mg/kg), and 
36·1–72·0 mg/kg (60 mg/kg). SAC doses ranged from 
13·5–28·7 mg/kg (20 mg/kg dose), 33·1–49·5 mg/kg 
(40 mg/kg), and 51·4–74·5 (60 mg/kg). The Emax model 
based on actual doses is shown in the appendix (p 4). The 
Emax model based on actual doses also showed a flat dose 
response for PSAC, whereas the response for SAC showed 
increasing efficacy at escalating dosages.
In an assessment of the cure rates for each S mansoni 
infection intensity category, we found that cure rates 
decreased as the infection intensity increased (table 2) in 
both age groups (PSAC or SAC) and at all praziquantel 
doses (appendix p 5).
Table 3 shows the number of treated children with 
adverse events and their dynamics over time. Adverse 
events data were available for 124 PSAC and 177 SAC. In 
the PSAC group, 30 children were absent (placebo [n=9], 
20 mg/kg [n=5], 40 mg/kg [n=9], and 60 mg/kg [n=7]) 
following treatment and were not assessed for adverse 
events. Before treatment, overall 78 (63%) of 124 PSAC and 
104 (59%) of 177 SAC reported mild symptoms. The 
recorded number of complaints was similar among 
treatment groups, with stomach ache and coughing most 
frequently reported. At 3 h post treatment, PSAC reported 
fewer symptoms compared with pre-treatment. In SAC 
there were slightly more reported episodes compared with 
pre-treatment at this timepoint. Overall, 29 (23%) of 
124 PSAC and 124 (70%) of 177 SAC reported adverse 
events 3 h post treatment. Most adverse events were mild 
(29 [91%] of 32 episodes in PSAC and 124 [98%] of 
126 episodes in SAC). No serious adverse events were 
reported. For both age groups, the number of adverse 
events was similar among the three praziquantel treatment 
groups, with fewer adverse events observed in the placebo 
groups. The most common adverse events in PSAC 3 h 
post treatment were diarrhoea (11 [9%] of 124) and stomach 
ache (ten [8%] of 124). Adverse events commonly observed 
in SAC were stomach ache (66 [37%] of 177), diarrhoea 
(50 [28%] of 177),  and headache (27 [15%] of 177; table 3).
24 h post-treatment, 16 episodes (13%) were noted by 
PSAC and 67 (38%) episodes by SAC. All reported 
adverse events were mild. No difference in the number 
of adverse events was noted among the different 
treatment groups and placebo group. Diarrhoea (six [5%] 
of 124) and vomiting (four [3%] of 124) were the two most 
common symptoms in PSAC 24 h post-treatment. 
Stomach ache (28 [16%] of 177), cough (20 [11%] of 177), 
and diarrhoea (18 [10%] of 177) were most frequently 
observed in SAC. Adverse events observed 48 h and 72 h 
post treatment are presented in the appendix p (6).
Discussion
In the absence of a paediatric formulation of praziquantel, 
the accurate management of young children with 
schistosomiasis at point-of-care and at community levels 
may be challenging. Yet, by focusing treatment in 
preventive chemotherapy programmes on the school-
aged population, children of preschool age are neglected, 
thus preventing them from benefiting from treatment 
given to their older peers, and hence creating a potential 
health inequity. If children as young as age 2 years can be 
infected (as shown in ours and previous studies),12,22 but 
must wait until school age to be treated, they are probably 
already facing consequences of the chronic infection at a 
young age, which might carry on into older age. At the 
moment, praziquantel is widely used off-label at a 
standard dose of 40 mg/kg to treat PSAC, because this is 
the dose used for SAC and adults.25,28–30 However, the 
effective dose for children younger than 4 years is 
unknown. Although the efficacy and safety of praziquantel 
has been intensively assessed in SAC,28–30 and more 
recently in PSAC,31–34 surprisingly, well designed dose–
response relation studies are lacking in both age groups.
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Figure 2: Cure rates in PSAC (blue lines) and SAC (red lines)
Circles show observed cure rates with 95% CIs (vertical lines). Numbers and 
colour code in the circles show geometric mean infection intensities at baseline 
(BL). Dashed lines represent the estimated dose–response curve and 
corresponding 95% confidence bands predicted by the Emax models. Epg=eggs 
per gram of stool. PSAC=preschool-aged children. SAC=school-aged children.
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Figure 3: Egg reduction rates in PSAC (blue lines) and SAC (red lines)
Diamonds show observed cure rates with 95% CIs (vertical lines). Dashed lines 
represent the estimated dose response curve and corresponding 95% confidence 
bands predicted by the Emax model. PSAC=preschool-aged children. SAC=school-
aged children.
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Our randomised controlled trial, assessing the efficacy 
and safety of 20 mg/kg, 40 mg/kg, and 60 mg/kg 
praziquantel in PSAC and SAC to uncover the nature of 
the dose-related effect, aimed to fill this gap. We used 
baseline and follow-up surveys at a reasonably sensitive 
diagnostic approach aiming for four Kato-Katz thick 
smears for the diagnosis of S  mansoni in all study 
participants. Additionally, a urine POC-CCA cassette test 
was used for diagnosis of S mansoni.
In SAC, an increasing efficacy was noted with 
escalating doses of praziquantel. The highest cure rate 
and ERR (geometric mean) were observed with 
60 mg/kg praziquantel. The Emax model predicted an 
ERR of 99·0% at 65 mg/kg in SAC (figure 3). 60 mg/kg 
showed a slightly better performance than did 40 mg/kg 
praziquantel in terms of cure rate and ERR; however, 
the overlapping confidence intervals suggest that both 
doses perform similarly. Our findings are in line with a 
recent meta-analysis, which reported a cure rate 
of 74·6% (95% CI 68·3–80·6) using 40 mg/kg 
praziquantel to treat S mansoni infections in SAC, and a 
significant relation between the cure rates and dose in 
the treatment of S mansoni.27 In addition, a multicentre 
study comparing the efficacy of 40 mg/kg versus 
60 mg/kg praziquantel concluded that the higher dose 
offers no significant efficacy advantage over the 
standard dose.28
We did not identify a no-effect dose range in PSAC. 
Moderate cure rate and ERR were observed with 
20 mg/kg (cure rate of 62·1%; ERR of 90·7%), which 
slightly increased when 40 mg/kg (cure rate of 72·2%; 
ERR of 94·8%) or 60 mg/kg (cure rate of 71·4%; ERR 
of 95·8%) were given. The Emax model predicted that in 
PSAC an ERR of 99% is out of the observed range. If we 
calculate arithmetic means, then ERRs in PSAC ranged 
from 80·9–84·1%. Hence, cure rates and ERRs were 
Preschool-aged children (PSAC) School-aged children (SAC)
Placebo Praziquantel 
20 mg/kg
Praziquantel 
40 mg/kg
Praziquantel 
60 mg/kg
Placebo Praziquantel 
20 mg/kg
Praziquantel 
40 mg/kg
Praziquantel 
60 mg/kg
Kato-Katz
Infected children 
before treatment
35 37 36 35 42 46 45 41
Cured children after 
treatment
13 
(37·1%; 
21·5–55·1)
23 
(62·2%; 
44·8–77·5)
26 
(72·2%; 
54·8–85·8)
25 
(71·4%; 
53·7–85·4)
5 
(11·9%; 
4·0–25·6)
14 
(30·4%; 
17·7–45·8)
31 
(68·9%; 
53·4–81·8)
34 
(82·9%; 
67·9–92·8)
Cured children by infection intensity†
Low 11/27 19/27 23/30 21/26 5/24 11/25 16/17 19/20
Moderate 2/6 4/8 3/6 3/8 0/14 3/16 10/15 9/10
Heavy 0/2 0/2 0/0 1/1 0/4 0/5 5/13 6/11
Geometric mean EPG
Before treatment 40·0 31·7 24·7 39·4 71·7 76·5 84·1 80·2
After treatment 7·9 2·9 1·3 1·7 31·5 12·1 1·4 0·7
Egg reduction rate 80·1% 
(66·3–88·9)
90·7% 
(82·0–95·7)
94·8% 
(89·1–98·0)
95·8% 
(90·2–98·5)
56·0% 
(36·9–69·7)
84·2% 
(70·9–91·5)
98·3% 
(96·7–99·3)
99·1% 
(97·9–99·8)
Arithmetic mean EPG
Before treatment 112·3 140·1 56·5 87·6 179·6 193·7 220·3 292
After treatment 45·6 26·8 9·0 16·1 132·9 80·2 7·3 29·4
Egg reduction rate 59·4% 
(21·6–76·3)
80·9% 
(56·4–88·6)
84·1% 
(61·9–94·6)
81·6% 
(57·1–94·6)
26·0% 
(0–58·5)
58·6% 
(24·1–75·9)
96·7% 
(93·2–98·0)
89·9% 
(61·9–99·5)
POC-CCA* (with ‘’trace’’ as positive)
Infected children 
before treatment
28 26 25 24 37 42 39 40
Cured children after 
treatment 
6 
(21·4%; 8·3–40·9)
4 
(15·4%; 4·4–34·9)
8 
(32·0%; 14·9–53·5)
8 
(33·3%; 15·6–55·3)
4 
(10·8%; 3·0–25·4)
8 
(19·0%; 8·6–34·1)
15 
(38·5%; 23·4–55·4)
22 
(55·0%; 38·5–70·7)
POC-CCA (with ‘’trace’’ as negative)
Infected children 
before treatment
24 23 21 23 33 38 35 35
Cured children after 
treatment
4 
(16·7%; 4·7–37·4)
5 
(21·7%; 7·5–43·7)
7 
(33·3%; 14·6–57·0)
12 
(52·2%; 30·6–73·2)
4 
(12·1%; 3·4–28·2)
11 
(28·9%; 15·4–45·9)
16 
(45·7%; 28·9–63·3)
23 
(65·7%; 47·8–80·9)
Data are n, n (%), n/N, or n (%; 95% CI). EPG=eggs per gram. POC-CCA=Point-of-Care Circulating Cathodic Antigen cassette test. *POC-CCA tests were applied on the first urine sample collected from each participant on 
the first day of collection. Among PSAC and SAC, respectively (seven vs five) in placebo, (11 vs four) in 20 mg/kg, (11 vs six) in 40 mg/kg, and (11 vs one) in 60 mg/kg did not provide urine samples on the first day of urine 
collection †Schistosoma mansoni infection intensity was stratified into low (1–99 EPG), moderate (100–399 EPG), and heavy (≥400 EPG) infection.
Table 2: Available case analysis of cure and egg reduction rates of 20 mg/kg, 40 mg/kg¸ and 60 mg/kg praziquantel versus placebo against intestinal schistosomiasis in PSAC and SAC 
based on Kato-Katz and POC-CCA
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lower at 40 mg/kg and 60 mg/kg praziquantel in PSAC 
compared with in SAC (regardless of diagnostic tool). 
Notably, recent WHO Standard Operating Procedures 
suggested a reference drug efficacy value of 90% or 
higher based on arithmetic means for treating S mansoni 
infections with praziquantel.35 All doses investigated in 
PSAC—namely, 20 mg/kg, 40 mg/kg, and 60 mg/kg—
would therefore not fulfil the criteria of clinical efficacy. 
Enzymatic processes and the immune system have been 
well documented to be age-dependent and might affect 
the absorption, distribution, metabolism, and 
elimination of drugs in young children.18,20,21,36 Because 
SAC were treated side-by-side with the same 
praziquantel dosages, in the same ecological setting 
(villages were all within a radius of 5 km), using the 
same diagnostic tests, and administering the same food 
item, confounding factors can be ruled out. However, 
crushing the tablets might have altered the bioavailability 
and pharmacokinetic properties of praziquantel and 
might therefore play a part in the difference in efficacy 
noted in PSAC.
The efficacy observed for 40 mg/kg in PSAC 
corresponds with results reported by the above-
mentioned meta-analysis,27 which calculated a cure rate 
of 69% and an ERR of 85·6% for this praziquantel dose 
in PSAC. A recent study in a small cohort in Ugandan 
Preschool-aged children (PSAC) School-aged children (SAC)
Placebo 
(n=27*)
Praziquantel 
20 mg/kg 
(n=35*)
Praziquantel 
40 mg/kg 
(n=29*)
Praziquantel 
60 mg/kg 
(n=33*)
Overall 
(n=124)
Placebo 
(n=42)
Praziquantel 
20 mg/kg 
(n=47)
Praziquantel 
40 mg/kg 
(n=46)
Praziquantel 
60 mg/kg 
(n=42)
Overall 
(n=177)
Before treatment
Moderate 0 0 0 0 0 0 0 0 0 0
Mild 19 (70%) 21 (60%) 17 (59%) 21 (64%) 78 (63%) 22 (52%) 29 (62%) 28 (61%) 25 (60%) 104 (59%)
None 8 (30%) 14 (40%) 12 (41%) 12 (36%) 46 (37%) 20 (48%) 18 (38%) 18 (39%) 17 (40%) 73 (41%)
Stomach ache 3 (11%) 3 (9%) 8 (28%) 4 (12%) 18 (15%) 12 (29%) 6 (13%) 10 (22%) 8 (19%) 36 (20%)
Cough 9 (33%) 11 (31%) 10 (35%) 6 (18%) 36 (2%9) 10 (24%) 22 (47%) 20 (43%) 14 (33%) 66 (37%)
Diarrhoea 6 (22%) 6 (17%) 4 (14%) 5 (15%) 21 (17%) 4 (10%) 2 (4%) 7 (15%) 0 13 (7%)
Headache 0 2 (6%) 0 1 (3%) 3 (2%) 5 (12%) 5 (11%) 1 (2%) 6 (14%) 17 (10%)
Vomiting 2 (7%) 0 3 (10%) 1 (3%) 6 (5%) 2 (5%) 2 (4%) 1 (2%) 2 (5%) 7 (4%)
Itching 2 (7%) 2 (6%) 2 (7%) 4 (12%) 10 (8%) 1 (2%) 3 (6%) 2 (4%) 1 (2%) 7 (4%)
Fever 3 (11%) 7 (20%) 7 (24%) 11 (33%) 28 (23%) 0 0 1 (2%) 2 (5%) 3 (2%)
3 h post treatment
Moderate 0 1 (3%) 2 (7%) 0 3 (2%) 1 (2%) 0 0 1 (2%) 2 (1%)
Mild 3 (11%) 7 (20%) 8 (28%) 11 (33%) 29 (23%) 20 (48%) 36 (77%) 36 (78%) 32 (76%) 124 (70%)
None 24 (89%) 27 (77%) 19 (66%) 22 (67%) 92 (74%) 21 (50%) 11 (23%) 10 (22%) 9 (21%) 51 (29%)
Stomach ache 0 1 (3%) 5 (17%) 4 (12%) 10 (8%) 11 (26%) 22 (47%) 17 (37%) 16 (38%) 66 (37%)
Cough 0 2 (6%) 2 (7%) 2 (6%) 6 (5%) 3 (7%) 8 (17%) 4 (9%) 9 (21%) 24 (14%)
Diarrhoea 1 (4%) 5 (14%) 2 (7%) 3 (9%) 11 (9%) 5 (12%) 12 (26%) 17 (37%) 16 (38%) 50 (28%)
Headache 1 (4%) 1 (3%) 1 (3%) 0 3 (2%) 4 (10%) 7 (15%) 5 (11%) 11 (26%) 27 (15%)
Vomiting 0 1 (3%) 1 (3%) 2 (6%) 4 (3%) 2 (5%) 7 (15%) 9 (20%) 8 (19%) 26 (15%)
Itching 0 0 0 0 0 1 (2%) 3 (6%) 2 (4%) 1 (2%) 7 (4%)
Fever 1 (4%) 1 (3%) 0 0 2 (2%) 2 (5%) 2 (4%) 0 1 (2%) 5 (3%)
24 h post treatment
Moderate 0 0 0 0 0 0 0 0 0 0
Mild 4 (15%) 5 (14%) 1 (3%) 6 (18%) 16 (13%) 16 (38%) 17 (36%) 18 (39%) 16 (38%) 67 (38%)
None 23 (85%) 30 (86%) 28 (97%) 27 (82%) 108 (87%) 26 (62%) 30 (64%) 28 (61%) 26 (62%) 110 (62%)
Stomach ache 0 0 0 0 0 7 (17%) 9 (19%) 4 (9%) 8 (19%) 28 (16%)
Cough 0 0 0 2 (6%) 0 5 (12%) 5 (11%) 5 (11%) 5 (12%) 20 (11%)
Diarrhoea 0 5 (14%) 0 1 (3%) 6 (5%) 5 (12%) 4 (9%) 3 (7%) 6 (14%) 18 (10%)
Headache 1 (4%) 0 1 (3%) 1 (3%) 3 (2%) 2 (5%) 2 (4%) 3 (7%) 4 (10%) 11 (6%)
Vomiting 2 (7%) 1 (3%) 0 1 (3%) 4 (3%) 2 (5%) 2 (4%) 3 (7%) 4 (10%) 11 (6%)
Itching 0 0 0 1 (3%) 0 4 (10%) 3 (6%) 3 (7%) 3 (7%) 13 (7%)
Fever 1 (4%) 0 0 1 (3%) 2 (2%) 1 (2%) 0 0 0 1 (1%)
Data are n (%). *30 kids were absent (placebo [n=9], 20 mg/kg [n=5], 40 mg/kg [n=9], and 60 mg/kg [n=7]) following treatment and were not assessed for adverse events.
Table 3: Main type of clinical symptoms before treatment and adverse events 3 h and 24 h after praziquantel administration in SAC (n=177) and 
PSAC (n=124)
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children showed higher cure rates and ERRs with 
60 mg/kg praziquantel (ERR 91%, cure rate 82%) versus 
40 mg/kg (ERR 82%, cure rate 70%),34 however two-thirds 
of the examined children were school-aged and hence no 
real conclusion on the efficacy of praziquantel on young 
children could be drawn.
One limitation of our study was that, based on the 
tablet formulation used in the current study (600 mg 
praziquantel tablets; Cesol), only half tablets increments 
(ie, 300 mg) could be given. Using tablets, which could 
have been divided in four parts (ie, Distocide) could have 
allowed us to dose slightly more accurately. As proposed 
recently by Olliaro and colleagues in 2013,31 we strongly 
recommend that when working with PSAC, a formulation 
that can be divided into four parts (to give 150 mg 
increments) be used, particularly in children weighing 
less than 10 kg as long as a novel paediatric formulation 
based on oral dispersible tablets is under development.
Another limitation of our study is a high proportion of 
PSAC treated with placebo showing no eggs at the follow-
up using the Kato-Katz technique. The Kato-Katz method 
has been well documented to be less sensitive, especially 
in populations with low infection intensity such as PSAC 
or in communities having received treatment. In our 
study, most PSAC had a light infection intensity. 45 PSAC 
(about 14%) had only one single egg found in all four 
Kato-Katz thick smears taken together at baseline. 
In 2015, Siqueira and colleagues37 assessed parasitological 
and molecular techniques for the diagnosis and 
assessment of cure in individuals infected with S mansoni 
harbouring a light infection and concluded that an 
increased number of Kato-Katz slides or a test with 
higher sensitivity is required for participants with a very 
low parasite load situation, such as after therapeutic 
interventions. Our study therefore included the sensitive 
POC-CCA cassette test as an alternative diagnostic 
instrument. As expected, cure rates were significantly 
lower using the POC-CCA compared with the Kato-Katz, 
but across all treatment groups, due to the higher 
sensitivity of this device.38 However, this finding does not 
only point to treatment failures of chronic S mansoni 
infections. Indeed, praziquantel is largely refractory 
against young developing stages of the worms,14 and 
hence antigens might be present in the urine of young 
children due to acute infections contributing to the low 
cure rates observed with POC-CCA in this study.
The nature of the dose–response relation based on 
POC-CCA were similar to the one observed with Kato-
Katz in SAC. Regardless of whether traces were 
considered as positive or negative, a dose–response 
relation was observed in SAC with the highest efficacy 
observed for SAC at 60 mg/kg (55·0 and 65·7% cure 
rate, respectively). In PSAC, similar cure rates were 
observed at 40 mg/kg and 60 mg/kg considering traces 
as positive (32·0% and 33·3%), which were higher than 
the ones recorded for 20 mg/kg (cure rate of 15·4%). 
However, when considering traces as negative, increasing 
cure rates were observed with increasing dosages in this 
group (21·7–52·2%). Of note, debate is still ongoing 
about the correct interpretation to give to POC-CCA 
“trace” scores in the diagnosis of S mansoni,39 hence the 
Kato-Katz diagnosis remains the diagnostic of choice at 
the moment, also for regulators.
We found that praziquantel at the investigated doses, 
was well tolerated by SAC and PSAC with only mild 
adverse events observed over time. Almost all adverse 
events disappeared within the 24 h following praziquantel 
administration. Our findings are in line with previous 
studies assessing safety of praziquantel in SAC28–30 and 
PSAC.31–33 Several issues are worth highlighting. First, 
fewer adverse events were noted in the placebo group 
compared with the praziquantel groups for both age 
groups. Second, no statistical difference was observed in 
the number of adverse events between treatment groups. 
Praziquantel shows good tolerability even at the highest 
dosage of 60 mg/kg. Third, although the frequency of 
adverse events peaked at 3 h post treatment in SAC; in 
PSAC, fewer clinical symptoms were reported 3 h 
post treatment compared with symptoms before 
treatment. However, we note that mothers were acting 
on behalf of their children in the statement of adverse 
events which could strongly influence this result.
In conclusion, praziquantel shows lower efficacies in 
PSAC compared with in SAC with none of the doses 
achieving a satisfactory ERR based on WHO guidelines34 
and moderate cure rates observed at all doses. However, 
in the absence of alternative treatments, a single dose of 
praziquantel (40 mg/kg), as recommended by WHO can 
be recommended for both S mansoni infections in PSAC 
and SAC in preventive chemotherapy programmes.
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